International Journal of Occupational and Environmental Health Features Discovery of Asbestos-Related Pain Origin from Scientists at the Karmanos Cancer Institute in Detroit
"This action of the pleural plaque against the covering of the bone and the bone itself is a biologically plausible and an anatomically logical
explanation of the unrelenting pain which some patients experience," said Dr. Harbut.
This new imaging approach involves enhancing images ob...
Logical Therapeutics Appoints Peter A. Lankau as CEO and Director
WALTHAM, Mass., May 11 /PRNewswire/ -- logical
Therapeutics, Inc (Logical), a biotechnology compa...rer.
"We are delighted to have Peter join the logical
team and our Board of Directors," said Lutz Giebel, Chairman of logical
Therapeutics, Inc., and the Managing Partner of SV...
Spherix Postpones 2009 Annual Shareholders Meeting to Share Interim Diabetes Clinical Trial Data
...x, said, "Postponing this year's Annual Shareholders Meeting until we are able to share the results of the interim analysis with our shareholders is a logical
decision for us. We believe this will be a significant moment for both Spherix and its shareholders, and we are enthusiastic about the trial's potent...
Logical Therapeutics Inc. Commences Double-Blind, Randomized Study of Their Lead Program, LT-NS001
... WALTHAM, Mass., Sept. 8 /PRNewswire/ -- logical
announced today the commenceme...ant safety problem," said
Lutz Giebel, Chairman of logical
Therapeutics. Published studies have shown
that NS...k, who resigned to pursue other interests.
Two New Alzheimer's Disease Studies Show Advances Against Different Treatment Targets
...Mental State Exam scores =24, self-reported memory
complaint corroborated by spouse or companion, and Wechsler Memory Scale
III (WMS-III) age-adjusted logical
Memory II score =5. One hundred
forty-four (144) subjects were randomized at 16 centers in the U.S.
Cognitive tests were conducted four weeks prior to...
Patient Receives vProtect(TM) Luminal Shield in First-Ever Vulnerable Plaque Clinical Trial
stabilized the target lesions.
According to Professor Patrick W. Serruys, MD, PhD, of Erasmus
University, the SECRITT I trial represents the logical
extension of modern
cardiac medicine: "We are very good at opening arteries that are blocked,
but we have not succeeded in preventing heart attacks re...
Sunesis Pharmaceuticals Initiates Phase 2 Clinical Trial of Voreloxin (SNS-595) in Acute Myeloid Leukemia
...N Council serves health professionals
in the United States by selecting simple, informative, and unique
nonproprietary names for drugs by establishing logical
classifications based on pharmacological and/or chemical relationships to
ensure that drug information is communicated accurately and una...
National Wrestling Coaches Association Teams Up With CSG/SportsCoatings(TM)
...ings CEO Craig Andrews. "Working with a group like the NWCA
that values educating wrestlers about proactive measures in health and
safety was the next logical
step for our company."
"Taking proactive measures to protect wrestling equipment and
protective gear from bacteria mold and fungi common in wrestlin...
Cethromycin Achieves All Endpoints in Second Pivotal Phase III Trial for Treatment of Pneumonia
... (mITT) 83.1% 81.1% 82.9% 88.5% 83.0% 84.8% (217/261)(206/254)(213/257)(224/253)(430/518)(430/507)[-6.4,+2.8] Bacterio- logical
Cure Rate (PPb) 95.9% 97.1% 89.1% 96.8% 92.7% 97.0% (70/73) (67/69) (57/64) (61/63) (127/137)(128/132) NA
An Open Letter to Parents, Students, School Administrators, & Health Care Officials from Soapopular(R)
... now available throughout the US and
worldwide. We're passionate about the quality of our product, and we're determined
that alcohol-free is the most logical
and most pragmatic hand sanitizing
alternative. We're ready to put our resources into your hands, and offer a
national proposition. -- We invite an...
Arpida Announces Promising Results of "First-In-Man" Studies With
jiroveci. However, because they deliver high drug concentrations at
the site of infection with negligible systemic absorption, they are
complements to standard intravenous therapy for severe
nosocomial pneumonias and in the treatment of severe
healthcare-associated pneumonia caused by ...
Presentations at American College of Cardiology Meeting Highlight
New Opportunities for HDL Therapy
... wide range of presentations at the recent American College of
Cardiology (ACC) Meeting in New Orleans that the rationale for HDL
being the next, most logical
target for the development of
treatments for cardiovascular disease continues to exhibit enormous
potential. This conclusion is even more compelling i...
Introgen Presents ADVEXIN Biomarker Data at Major Cancer Conference
...lecular defects in cancer. ADVEXIN's
mechanism of action is targeted to restoring p53 tumor suppressor
function and the detection of abnormal p53 is a logical
biomarker for ADVEXIN efficacy. In a study of 28 recurrent head and
neck cancer patients in Phase 2 clinical trials, abnormal p53 was
Labtec’s Next Generation Pain Patch Successful in Clinical
generic companies in Europe, we are looking forward to see our
Sufentanil TDS® move forward. In our opinion this transdermal
patch is the logical
next generation product for severe chronic
pain. Sufentanil is one of the most potent drugs in its class,
seven times more potent than Fentanyl and at...
Human Genome Sciences Reports Growing Evidence That Its TRAIL
Receptor Antibodies Have Significant Potential in the Treatment of
a Broad Range of Cancers
ahead with these agents will be increasing our understanding of the
biologic mechanisms underlying tumor response versus resistance,
combinations that counter these resistant
mechanisms, and considering appropriate patient selection to enrich
for a responsive population."
Lilly Studies Try to Shed Light on Impact of Race on Lung Cancer
...r of these two studies. "Because lung cancer
is a particularly devastating disease, and a growing concern in the
African-American population, it was a logical
starting point for
The GEMZAR study released at ASCO analyzed overall survival data
from a previous randomized Phase III trial in the...